Peptomyc Tackling ‘Undruggable’ Myc For Anticancers

CEO Laura Soucek Takes Issue With Scientific Dogma

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.

Cancer cells on scientific background.3d illustration
• Source: Shutterstock

After more than a decade or so researching the potential role of inhibiting the nuclear protein Myc in the treatment of cancer, researcher and entrepreneur Laura Soucek believes the next year or so could be pivotal in finding out if such an approach has promise.

“I’m terrified and excited at the same time, but really looking forward to the results,” said Soucek, co-founder and CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo